Fagan Associates Inc. cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,230 shares of the biopharmaceutical company’s stock after selling 870 shares during the period. Gilead Sciences makes up 1.2% of Fagan Associates Inc.’s investment portfolio, making the stock its 28th largest position. Fagan Associates Inc.’s holdings in Gilead Sciences were worth $2,189,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Hall Laurie J Trustee raised its stake in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. raised its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the period. Penserra Capital Management LLC raised its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the period. Finally, Webster Bank N. A. raised its stake in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the period. Hedge funds and other institutional investors own 74.04% of the company’s stock.

Gilead Sciences, Inc. (GILD) traded up 0.70% on Tuesday, hitting $75.21. 2,918,788 shares of the company’s stock traded hands. The stock has a market cap of $98.22 billion, a PE ratio of 8.17 and a beta of 1.21. The stock has a 50-day moving average of $72.97 and a 200-day moving average of $68.86. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $82.07. Gilead Sciences also was the recipient of some unusual options trading activity on Monday. Investors bought 19,878 put options on the stock. This represents an increase of approximately 209% compared to the average daily volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter last year, the business earned $3.08 earnings per share. The business’s revenue for the quarter was down 8.2% compared to the same quarter last year. On average, equities analysts forecast that Gilead Sciences, Inc. will post $8.74 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.78%. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/fagan-associates-inc-has-2-19-million-stake-in-gilead-sciences-inc-gild/1530049.html.

A number of brokerages have issued reports on GILD. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target for the company in a research note on Tuesday, May 2nd. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.34 price target for the company. in a research note on Thursday, May 11th. Stifel Nicolaus reiterated a “buy” rating and issued a $87.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Gabelli reiterated a “buy” rating and issued a $85.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Finally, Deutsche Bank AG began coverage on Gilead Sciences in a research note on Friday, June 23rd. They issued a “buy” rating and a $79.00 price target for the company. Eleven analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $80.83.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock valued at $15,223,184 over the last 90 days. 1.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.